126 related articles for article (PubMed ID: 7596122)
1. Infarct size-limiting properties of Ro 40-5967, a novel nondihydropyridine calcium channel, in anesthetized rats: comparison with verapamil.
Richard V; Tron C; Blanc T; Thuillez C
J Cardiovasc Pharmacol; 1995 Apr; 25(4):552-7. PubMed ID: 7596122
[TBL] [Abstract][Full Text] [Related]
2. The novel calcium antagonist Ro 40-5967 limits myocardial infarct size in the dog.
Vander Heide RS; Schwartz LM; Reimer KA
Cardiovasc Res; 1994 Oct; 28(10):1526-32. PubMed ID: 8001041
[TBL] [Abstract][Full Text] [Related]
3. Effects of mibefradil, a novel calcium channel blocking agent with T-type activity, in acute experimental myocardial ischemia: maintenance of ventricular fibrillation threshold without inotropic compromise.
Muller CA; Opie LH; McCarthy J; Hofmann D; Pineda CA; Peisach M
J Am Coll Cardiol; 1998 Jul; 32(1):268-74. PubMed ID: 9669280
[TBL] [Abstract][Full Text] [Related]
4. Mibefradil, a T-type and L-type calcium channel blocker, limits infarct size through a glibenclamide-sensitive mechanism.
Mocanu MM; Gadgil S; Yellon DM; Baxter GF
Cardiovasc Drugs Ther; 1999 Apr; 13(2):115-22. PubMed ID: 10372226
[TBL] [Abstract][Full Text] [Related]
5. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil.
Clozel JP; Banken L; Osterrieder W
J Cardiovasc Pharmacol; 1989 Nov; 14(5):713-21. PubMed ID: 2481185
[TBL] [Abstract][Full Text] [Related]
6. The structurally novel Ca2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts.
Clozel JP; Véniant M; Osterrieder W
Cardiovasc Drugs Ther; 1990 Jun; 4(3):731-6. PubMed ID: 1963792
[TBL] [Abstract][Full Text] [Related]
7. Ro 40-5967, a novel calcium channel antagonist, protects against ventricular fibrillation.
Billman GE
Eur J Pharmacol; 1992 Dec; 229(2-3):179-87. PubMed ID: 1490522
[TBL] [Abstract][Full Text] [Related]
8. Unique cardioprotective action of the new calcium antagonist mibefradil.
Schulz R; Post H; Jalowy A; Backenköhler U; Dörge H; Vahlhaus C; Heusch G
Circulation; 1999 Jan; 99(2):305-11. PubMed ID: 9892599
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic profile of Ro 40-5967 in conscious rats: comparison with diltiazem, verapamil, and amlodipine.
Véniant M; Clozel JP; Hess P; Wolfgang R
J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S55-8. PubMed ID: 1725005
[TBL] [Abstract][Full Text] [Related]
10. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
Sandmann S; Spitznagel H; Chung O; Xia QG; Illner S; Jänichen G; Rossius B; Daemen MJ; Unger T
Cardiovasc Res; 1998 Aug; 39(2):339-50. PubMed ID: 9798519
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of mibefradil, verapamil, and amlodipine on myocardial function and intracellular Ca(2+) handling in rats with chronic myocardial infarction.
Min JY; Sandmann S; Meissner A; Unger T; Simon R
J Pharmacol Exp Ther; 1999 Dec; 291(3):1038-44. PubMed ID: 10565822
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive properties of the novel calcium antagonist (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino] ethyl]-6- fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphthyl methoxyacetate dihydrochloride in rat models of hypertension. Comparison with verapamil.
Hefti F; Clozel JP; Osterrieder W
Arzneimittelforschung; 1990 Apr; 40(4):417-21. PubMed ID: 2357242
[TBL] [Abstract][Full Text] [Related]
13. Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats.
Sandmann S; Claas R; Cleutjens JP; Daemen MJ; Unger T
J Cardiovasc Pharmacol; 2001 Jan; 37(1):64-77. PubMed ID: 11152376
[TBL] [Abstract][Full Text] [Related]
14. Inadequate ischaemia-selectivity limits the antiarrhythmic efficacy of mibefradil during regional ischaemia and reperfusion in the rat isolated perfused heart.
Farkas A; Qureshi A; Curtis MJ
Br J Pharmacol; 1999 Sep; 128(1):41-50. PubMed ID: 10498833
[TBL] [Abstract][Full Text] [Related]
15. Reduction of myocardial ischemia-reperfusion injury by KT-362, a new intracellular calcium antagonist in anesthetized dogs.
Pelc LR; Farber NE; Warltier DC; Gross GJ
J Cardiovasc Pharmacol; 1989 Apr; 13(4):586-93. PubMed ID: 2470996
[TBL] [Abstract][Full Text] [Related]
16. Reduction in infarct size by ischemic preconditioning persists in a chronic rat model of myocardial ischemia-reperfusion injury.
Lott FD; Guo P; Toombs CF
Pharmacology; 1996 Feb; 52(2):113-8. PubMed ID: 8851632
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of effects of verapamil and those of nicardipine on myocardial ischemia and reperfusion injury: a study in an in situ rabbit model].
Furuya M; Yoshida K
Masui; 1999 Oct; 48(10):1074-82. PubMed ID: 10554498
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
Braun S; van der Wall EE; Emanuelsson H; Kobrin I
J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
[TBL] [Abstract][Full Text] [Related]
19. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
Portegies MC; Schmitt R; Kraaij CJ; Braat SH; Gassner A; Hagemeijer F; Pozenel H; Prager G; Viersma JW; van der Wall EE
J Cardiovasc Pharmacol; 1991 Nov; 18(5):746-51. PubMed ID: 1723772
[TBL] [Abstract][Full Text] [Related]
20. Effects of the calcium channel antagonist mibefradil on haemodynamic parameters and myocardial Ca(2+)-handling in infarct-induced heart failure in rats.
Sandmann S; Min JY; Meissner A; Unger T
Cardiovasc Res; 1999 Oct; 44(1):67-80. PubMed ID: 10615391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
